The Medical Letter on Drugs and Therapeutics
Pramlintide (Symlin) for Diabetes
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Pramlintide acetate (Symlin – Amylin Pharmaceuticals), a synthetic analog of human amylin, has been approved by the FDA as adjunctive treatment for patients with type 1 or type 2 diabetes who inject insulin at mealtimes and have failed to achieve glucose control. Pramlintide is injected subcutaneously before meals.

AMYLIN – Amylin is synthesized by pancreatic beta cells and co-secreted with insulin in response to food intake.

CLINICAL STUDIES — Administration of pramlintide to insulin-treated patients before a meal decreases post-prandial plasma glucose concentrations, limiting glucose fluctuations and decreasing the amount of short-acting insulin required. Several large, randomized, double-blind clinical trials evaluating pramlintide in patients with type 1 and type 2 diabetes being treated with insulin have been published; the results are summarized in the table on the ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Pramlintide (Symlin) for Diabetes
Article code: 1209b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian